Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Evommune, Inc. (NYSE:EVMN) have earned an average rating of “Moderate Buy” from the fourteen ratings firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, eight have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $43.25.

Several research analysts have issued reports on the stock. Wall Street Zen lowered shares of Evommune from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Weiss Ratings downgraded Evommune from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, June 29th. Stifel Nicolaus assumed coverage on Evommune in a research note on Friday, May 1st. They set a “buy” rating and a $54.00 price objective for the company. William Blair cut Evommune from an “outperform” rating to a “market perform” rating in a report on Monday, June 29th. Finally, Royal Bank Of Canada cut their target price on Evommune from $30.00 to $29.00 and set an “outperform” rating on the stock in a research report on Friday.

Evommune Trading Up 5.7%

NYSE:EVMN opened at $14.14 on Friday. Evommune has a twelve month low of $10.47 and a twelve month high of $33.20. The company has a 50-day moving average of $16.00 and a 200-day moving average of $21.16. The firm has a market cap of $509.15 million and a price-to-earnings ratio of -1.28.

Evommune (NYSE:EVMN) last released its earnings results on Thursday, August 6th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.21). On average, research analysts forecast that Evommune will post -2.83 earnings per share for the current year.

Insider Transactions at Evommune

In other Evommune news, insider Gregory S. Moss sold 14,223 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $22.83, for a total transaction of $324,711.09. Following the sale, the insider owned 60,835 shares in the company, valued at approximately $1,388,863.05. The trade was a 18.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Luis C. Pena sold 16,787 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $22.74, for a total transaction of $381,736.38. Following the completion of the transaction, the chief executive officer owned 637,896 shares of the company’s stock, valued at approximately $14,505,755.04. The trade was a 2.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 100,854 shares of company stock worth $2,279,142 in the last three months. Insiders own 31.10% of the company’s stock.

Hedge Funds Weigh In On Evommune

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. EQT Fund Management S.a r.l. acquired a new stake in Evommune during the 4th quarter valued at $84,395,000. RA Capital Management L.P. purchased a new stake in shares of Evommune in the fourth quarter valued at $59,214,000. Pivotal bioVenture Partners Investment Advisor LLC acquired a new stake in shares of Evommune in the fourth quarter worth $32,989,000. Nan Fung Group Holdings Ltd acquired a new stake in shares of Evommune in the fourth quarter worth $24,670,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of Evommune during the fourth quarter valued at $22,408,000.

About Evommune

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.